Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

A new scientific study has found that Pfizer’s COVID-19 vaccine may cause temporary changes in the eyes’ corneal structure, ...

The FDA action comes weeks after US Health Secretary Robert F. Kennedy Jr said the government would no longer recommend the COVID vaccine for healthy children or pregnant people.

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...